Authors



Rachel Burgoon, PharmD

Latest:

Increase in Enteroviruses Seen with Decreases in COVID-19 Precautions

The Centers for Disease Control and Prevention (CDC) reports the rise in pediatric acute respiratory illnesses especially as there is a decrease in hygiene measures that were previously employed during the pandemic.


Carl V. Crawford, MD

Latest:

Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections

To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.


Thumbi Ndung'u, BVM, PhD

Latest:

The FRESH Study Tests New HIV Remission Strategy in South African Women

Thumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.


Shawnalyn W. Sunagawa, PharmD, BCIDP

Latest:

A Chance to Improve Hepatitis C Care for PWID

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.


Michael J McElhaugh

Latest:

Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of Patients

Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.


Monica Gandhi, MD, MPH

Latest:

High-Resistance Therapy Options for Treatment-Naïve Patients With HIV

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.


Robert Bettiker, MD/MGA, FACP

Latest:

Resolution of Scurvy in a Patient With a Spinal Cord Injury

At 7.1%, vitamin C deficiency in the US is rare. Unfortunately, identifying scurvy is complex, frustrating, and time-consuming for both patient and provider.


Peter G. Collin, MD

Latest:

INSTIs and Cardiovascular Outcomes: More Complexity

The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.


Sunil Parikh, MD, MPH

Latest:

Ivermectin Does Not Reach Primary Endpoint in Burkina Faso Malaria Trial

Sunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).


Christina Rose, PharmD, BCCCP

Latest:

Oral Therapeutic Options to Prevent Disease Progression From COVID-19 in an Ambulatory Setting

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.


Sasirekha Ramani, PhD

Latest:

Advances in Mini Gut Organoid Models Reveal Key Insights into Norovirus Replication

Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.


Thu Le, PharmD

Latest:

A Penicillin Allergy Questionnaire for Outpatient Clinics

Clinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.


Katrine Wallace, PhD

Latest:

The Roles of Misinformation, Disinformation, and Confirmation Bias in Public Health Discourse

Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.


Ann-Marie Idusuyi, PharmD

Latest:

Ready, Set, Cabenuva: Implementing Cabotegravir/Rilpivirine

This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.


Camilo Mora, PhD

Latest:

When Climate Change Gets Personal: The Expanding Threat of Mosquito Habitats

As someone who lives with the long-term effects of chikungunya, Camillo Mora PhD, sees the expanding habitat of mosquitos and is concerned more people will be exposed to vector-borne illnesses and deal with not only the acute phases of these viruses but also the possibility of long-term health effects they can present.


Amy Rowley, PharmD

Latest:

Unmasking the Infodemic: The Impact of COVID-19 Misinformation on Public Health

Social media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.


Hawra Al-Lawati, MD

Latest:

Climate Change Effects on Vector-Borne Disease: The Case of Lyme

With evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.


Krutika Kuppalli, MD, FIDSA; and Syra Madad, DHSc, MSc

Latest:

Emerging Infectious Diseases During COVID-19

In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.


Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS

Latest:

Identifying Invasive Pneumococci in Pediatric Infections Utilizing Whole Genome Sequencing

This method represents a significant advancement in case management for this population. In our latest From Pathogen to Infectious Disease Diagnosis Podcast, Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, provides insights on its capabilities and how it can potentially aid clinicians in reducing antimicrobial resistance.


Luisa Stamm, MD, PhD

Latest:

Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ART

In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.


Georg Behrens, MD, PhD

Latest:

Bictegravir vs Darunavir in Advanced HIV: Results from the LAPTOP Trial

Georg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.


Andrea Prinzi, PhD, MPH, SM(ASCP)

Latest:

Are We at a Breaking Point for Adoption of Updated Susceptibility Interpretive Criteria?

The implementation of new College of American Pathologists rules presents an opportunity for collaboration between clinical microbiology laboratories and infectious disease pharmacists and physicians.


Jordan Mayberry, PA-C, MPAS

Latest:

The Future and Resources in HCV Care

Expert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.


Heather Saunders, MPH, RN, CIC

Latest:

The Overlooked Tropical Diseases You May Not Know About

Over 1 billion people are estimated to be affected by 20 conditions of neglected tropical diseases (NTDs), though they are often unheard of by many. Heather Saunders, MPH, RN, CIC, delves into 5 of these diseases and discusses efforts to stop their spread.


Sorana Segal-Maurer, MD

Latest:

HIV: Treating Patients with Viral Mutations

Sorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.


© 2025 MJH Life Sciences

All rights reserved.